Liver steatosis in hepatitis C positive hemodialysis patients and factors affecting IFN-2a treatment

References

• Fabrizi F, Martin P. Hepatitis C virus infection in dialysis: an emerging clinical reality. Int J Artif Organs 2001; 24: 123–30
   PubMed Web of Science ®Google Scholar
• Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335–42
   PubMed Web of Science ®Google Scholar
• Leblebicioglu H, Gunaydin M, Cengiz K, Islek I. Hepatitis markers in hemodialysis patients. Microbiol Bul 1993; 27: 321–6
   PubMedGoogle Scholar
• Sahin I, Arabaci F, Sahin HA, Ilhan M, Ustun Y, Mercan R, et al. Does hepatitis C virus infection increase hematocrit and hemoglobin levels in hemodialyzed patients?. Clin Nephrol 2003; 60: 401–4
   PubMed Web of Science ®Google Scholar
• Koksal I, Biberoglu K, Biberoglu S, Koc F, Ayma Y, Aker F, et al. Hepatitis C virus antibodies among risk groups in Turkey. Infection 1991; 19: 228–9
   PubMed Web of Science ®Google Scholar
• Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993; 44: 1322–6
   PubMed Web of Science ®Google Scholar
• McLaughlin K, Morris AJ. Antiviral treatment for HCV patients, pre-renal transplantation. Nephrol Dial Transplant 1997; 12: 1770–1
   PubMed Web of Science ®Google Scholar
• Muller GY, Zabaleta ME, Arminio A, Colmenares CJ, Capriles FI, Bianco NE, et al. Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int 1992; 41: 1055–8
   PubMed Web of Science ®Google Scholar
• Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435–40
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Locatelli F. Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist. Nephrol Dial Transplant 1999; 14: 2079–81
   PubMed Web of Science ®Google Scholar
• Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426–31
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315: 1575–8
   PubMed Web of Science ®Google Scholar
• Ellis ME, Alfurayh O, Halim MA, Sieck JO, Ali MA, Bernvil SS, et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 1993; 18: 210–6
   PubMed Web of Science ®Google Scholar
• Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology 1995; 26: 297–309
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824–32
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peg interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75–85
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106–15
   PubMed Web of Science ®Google Scholar
• Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880–5
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, et al. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001; 39: 119–24
   PubMed Web of Science ®Google Scholar
• Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–5
   PubMed Web of Science ®Google Scholar
• Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686–90
   PubMed Web of Science ®Google Scholar
• Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39: 728–30
   PubMed Web of Science ®Google Scholar
• Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterology 2003; 9: 1610–5
   Google Scholar
• Daichou Y, Kurashige S, Hashimoto S, Suzuki S. Characteristic cytokine products of Th1 and Th2 cells in hemodialysis patients. Nephron 1999; 83: 237–45
   PubMed Web of Science ®Google Scholar
• Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. Kidney Int Suppl 1997; 62: 79–82
   PubMed Web of Science ®Google Scholar
• Hanrotel C, Toupance O, Lavaud S, Thiefin G, Brodard V, Ingrand D, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 120–6
   PubMed Web of Science ®Google Scholar
• Chemello L, Alberti A, Rose K, Simmonds P. The hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330: 143
   PubMed Web of Science ®Google Scholar
• Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, et al. Efficacy and tolerance of α-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Intern 1995; 471: 412–8
   Google Scholar
• Bozdayi G, Rota S, Verdi H, Derici U, Sindel S, Bali M, et al. The presence of hepatitis C virus (HCV) infection in hemodialysis patients and determination of HCV genotype distribution. Mikrobiyol Bul 2002; 36: 291–300
   PubMedGoogle Scholar
• Abacioglu YH, Davidson F, Tuncer S, Yap PL, Ustacelebi S, Yulug N, et al. The distribution of hepatitis C virus genotypes in Turkish patients. J Viral Hepat 1995; 2: 297–301
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon alfa-2b in hemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. J Viral Hepatitis 1997; 4: 113–9
   PubMed Web of Science ®Google Scholar
• Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on hemodialysis. Nephrol Dial Transplant 1997; 12: 1414–9
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164–72
   PubMed Web of Science ®Google Scholar
• Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187–99
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517–24
   PubMed Web of Science ®Google Scholar
• Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999; 116: 378–86
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–13
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131–7
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33: 704–7
   PubMed Web of Science ®Google Scholar
• Mekki K, Prost J, Bouchenak M, Remaoun M, Belleville J. Plasma lipoprotein lipase, hepatic lipase activities, VLDL, LDL compositions at different times of hemodialysis. Atherosclerosis 2003; 169: 269–77
   PubMed Web of Science ®Google Scholar